Effects of rasagiline on olfactory function in patients with Parkinson’s disease.
Identifieur interne : 000682 ( PubMed/Curation ); précédent : 000681; suivant : 000683Effects of rasagiline on olfactory function in patients with Parkinson’s disease.
Auteurs : Antje Haehner ; Thomas Hummel ; Martin Wolz ; Lisa Klingelhöfer ; Mareike Fauser ; Alexander Storch ; Heinz ReichmannSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.
English descriptors
- KwdEn :
- Administration, Intranasal, Aged, Double-Blind Method, Electroencephalography, Evoked Potentials, Female, Humans, Indans (therapeutic use), Male, Middle Aged, Neuroprotective Agents (therapeutic use), Olfaction Disorders (drug therapy), Olfaction Disorders (etiology), Olfactometry, Parkinson Disease (complications), Prospective Studies, Psychophysics, Quality of Life, Severity of Illness Index.
- MESH :
- chemical , therapeutic use : Indans, Neuroprotective Agents.
- complications : Parkinson Disease.
- drug therapy : Olfaction Disorders.
- etiology : Olfaction Disorders.
- Administration, Intranasal, Aged, Double-Blind Method, Electroencephalography, Evoked Potentials, Female, Humans, Male, Middle Aged, Olfactometry, Prospective Studies, Psychophysics, Quality of Life, Severity of Illness Index.
Abstract
Impairment of olfactory function is a well recognized nonmotor manifestation of Parkinson’s disease(PD). The aim of this investigation was to determine if the MAO-B inhibitor rasagiline can improve olfaction in PD patients.
DOI: 10.1002/mds.25661
PubMed: 24190245
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000682
Links to Exploration step
pubmed:24190245Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of rasagiline on olfactory function in patients with Parkinson’s disease.</title><author><name sortKey="Haehner, Antje" sort="Haehner, Antje" uniqKey="Haehner A" first="Antje" last="Haehner">Antje Haehner</name></author><author><name sortKey="Hummel, Thomas" sort="Hummel, Thomas" uniqKey="Hummel T" first="Thomas" last="Hummel">Thomas Hummel</name></author><author><name sortKey="Wolz, Martin" sort="Wolz, Martin" uniqKey="Wolz M" first="Martin" last="Wolz">Martin Wolz</name></author><author><name sortKey="Klingelhofer, Lisa" sort="Klingelhofer, Lisa" uniqKey="Klingelhofer L" first="Lisa" last="Klingelhöfer">Lisa Klingelhöfer</name></author><author><name sortKey="Fauser, Mareike" sort="Fauser, Mareike" uniqKey="Fauser M" first="Mareike" last="Fauser">Mareike Fauser</name></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name></author><author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="doi">10.1002/mds.25661</idno><idno type="RBID">pubmed:24190245</idno><idno type="pmid">24190245</idno><idno type="wicri:Area/PubMed/Corpus">000682</idno><idno type="wicri:Area/PubMed/Curation">000682</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of rasagiline on olfactory function in patients with Parkinson’s disease.</title><author><name sortKey="Haehner, Antje" sort="Haehner, Antje" uniqKey="Haehner A" first="Antje" last="Haehner">Antje Haehner</name></author><author><name sortKey="Hummel, Thomas" sort="Hummel, Thomas" uniqKey="Hummel T" first="Thomas" last="Hummel">Thomas Hummel</name></author><author><name sortKey="Wolz, Martin" sort="Wolz, Martin" uniqKey="Wolz M" first="Martin" last="Wolz">Martin Wolz</name></author><author><name sortKey="Klingelhofer, Lisa" sort="Klingelhofer, Lisa" uniqKey="Klingelhofer L" first="Lisa" last="Klingelhöfer">Lisa Klingelhöfer</name></author><author><name sortKey="Fauser, Mareike" sort="Fauser, Mareike" uniqKey="Fauser M" first="Mareike" last="Fauser">Mareike Fauser</name></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name></author><author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Aged</term><term>Double-Blind Method</term><term>Electroencephalography</term><term>Evoked Potentials</term><term>Female</term><term>Humans</term><term>Indans (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (therapeutic use)</term><term>Olfaction Disorders (drug therapy)</term><term>Olfaction Disorders (etiology)</term><term>Olfactometry</term><term>Parkinson Disease (complications)</term><term>Prospective Studies</term><term>Psychophysics</term><term>Quality of Life</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Indans</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Olfaction Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Olfaction Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Aged</term><term>Double-Blind Method</term><term>Electroencephalography</term><term>Evoked Potentials</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Olfactometry</term><term>Prospective Studies</term><term>Psychophysics</term><term>Quality of Life</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Impairment of olfactory function is a well recognized nonmotor manifestation of Parkinson’s disease(PD). The aim of this investigation was to determine if the MAO-B inhibitor rasagiline can improve olfaction in PD patients.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24190245</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>25</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>29</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>14</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Effects of rasagiline on olfactory function in patients with Parkinson’s disease.</ArticleTitle><Pagination><MedlinePgn>2023-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Impairment of olfactory function is a well recognized nonmotor manifestation of Parkinson’s disease(PD). The aim of this investigation was to determine if the MAO-B inhibitor rasagiline can improve olfaction in PD patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-four PD patients participated in this single-center, prospective, randomized, controlled,double-blind study. Seventeen patients were randomly assigned to rasagiline and 17 patients to placebo. Orthoand retronasal olfactory testing and recording of event related potentials were performed before and after 120 days of rasagiline versus placebo intake.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When comparing olfactory score differences between baseline and after 120 days between the 2 groups, the level of significance was not reached.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The primary end point of the study was not reached, and therefore, a specific effect of rasagiline on olfactory function in PD could not be demonstrated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haehner</LastName><ForeName>Antje</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hummel</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wolz</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Klingelhöfer</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Fauser</LastName><ForeName>Mareike</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Storch</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reichmann</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000281">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005071">Evoked Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007189">Indans</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000857">Olfaction Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064367">Olfactometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011601">Psychophysics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25661</ArticleId><ArticleId IdType="pubmed">24190245</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000682 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000682 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24190245
|texte= Effects of rasagiline on olfactory function in patients with Parkinson’s disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24190245" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |